CoChat
Sign Up
Cited by 125Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesCholesterol and Lipid Metabolism

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

Wang, Tzung-Dau, Chen, Wen-Jone, Lin, Jong-Wei, Cheng, Ching-Chih, Chen, Ming-Fong, Lee, Yuan-Teh·2003·Atherosclerosis
DOI 10.1016/s0021-9150(03)00296-x
Open this paper in CoChat — free account

Abstract

Given that combination therapy with statin plus fibrate confers a risk of myopathy, it is worthwhile to determine whether statin or fibrate monotherapy is associated with greater clinical benefit in individuals with combined hyperlipidemia. In this randomized double-blind study, we compared the efficacy of simvastatin and fenofibrate on indexes of endothelial function (flow-mediated dilation (FMD) of the brachial artery) and inflammatory markers (plasma high-sensitivity C-reactive protein (CRP), interleukin-1 beta (IL-1 beta), soluble CD40, and soluble CD40 ligand (sCD40L) levels), as surrogate indicators of future coronary heart disease (CHD), in patients with combined hyperlipidemia. A total of 70 patients with plasma triglyceride levels between 200 and 500 mg/dl and total cholesterol levels of >200 mg/dl were randomly assigned to receive either simvastatin (20 mg/day) (n=35) or micronized fenofibrate (200 mg/day) (n=35) for 8 weeks. Treatment with simvastatin was associated with significantly greater reduction of total cholesterol and low-density lipoprotein cholesterol (LDL-C), while the decrease in triglycerides was significantly greater in patients receiving fenofibrate. Both fenofibrate and simvastatin markedly reduced plasma levels of high-sensitivity CRP, IL-1 beta, and sCD40L, and improved endothelium-dependent FMD without mutual differences. The changes in plasma inflammatory markers did not correlate with baseline clinical characteristics in both groups. However, the improvement in FMD with fenofibrate treatment correlated inversely with baseline high-density lipoprotein cholesterol (HDL-C) levels, whereas the improvement in FMD with simvastatin treatment was positively related to HDL-C levels. Accordingly, in the subgroup with a baseline HDL-C of < or =40 mg/dl, only fenofibrate significantly improved the endothelium-dependent FMD. On the other hand, in the subgroup with HDL-C >40 mg/dl, only treatment with simvastatin achieved significant improvement in FMD. The data here indicate that in patients with combined hyperlipidemia, both fenofibrate and simvastatin have comparative beneficial effects on various inflammatory markers and differential beneficial effects on endothelial function according to baseline HDL-C levels. These findings should be validated by additional prospective studies, in which patients are stratified by baseline HDL-C prior to randomization.

Integrity signals

Registry

Crossref · 10.1016/s0021-9150(03)00296-x

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Fenofibrate treatment typically reduces serum triglycerides by a mean change of −93.7 mg/dL (−39.3%), increases high density lipoprotein cholesterol by +5.5 mg/dL (+12.4%), and reduces low density lipoprotein cholesterol by −17.9 mg/dL (−12.3%).

    “Typical changes in serum lipids as a result of FF treatment include clinically important mean reductions of serum triglycerides (TG) by a mean change of −93.7 mg/dL (−39.3%), increases of high density lipoprotein cholesterol (HDLC) by +5.5 mg/dL (+12.4%), and reductions in low density lipoprotein cholesterol (LDLC) by −17.9 mg/dL (−12.3%).”

    From Fenofibrate and metabolic syndrome (2010) · cites this paper as [35]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Wang, T.-D., Chen, W.-J., Lin, J.-W., Cheng, C.-C., Chen, M.-F., & Lee, Y.-T.
Affiliations
  • National Taiwan University (TW)
  • National Taiwan University Hospital (TW)
Corresponding author
Lee, Yuan-Teh
ORCID
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2003-10
Volume
170
Issue
2
Pages
315-323
ISSN
0021-9150 (ISSN-L)
DOI
10.1016/s0021-9150(03)00296-x
OpenAlex
W2083042102
Cited by
125
References
39
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2020: 1 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 2 · 2013: 3 · 2012: 3
FWCI
16.20
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Atherosclerosis (publishedVersion)
  • PubMed (publishedVersion)
Funders
American Heart Association
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
mixed dyslipidemia, fenofibrate, simvastatin, statin-fibrate combination therapy, endothelial function, flow-mediated dilation, inflammatory markers, high-sensitivity C-reactive protein, IL-1β, soluble CD40 ligand, HDL cholesterol, triglycerides, LDL cholesterol, coronary heart disease risk, statin-induced myopathy
MeSH terms
Hypolipidemic Agents, C-Reactive Protein, Double-Blind Method, Drug Therapy, Combination, Endothelium, Vascular, Female, Humans, Hyperemia, Hyperlipidemia, Familial Combined, Interleukin-1, Lipids, Male, Middle Aged, Fenofibrate, Vasodilation, Inflammation Mediators, CD40 Antigens, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, CD40 Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review